Amgen (AMGN) Bullish Stance Reiterated at Jefferies Following Repatha Panel Backing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
FDA Panel Points to Narrower Label for Amgen's (AMGN) Repatha, Nomura Notes
June 11, 2015 8:31 AM EDTNomura Securities analyst M. Ian Somaiya maintained his Buy rating and $182 price target on Amgen (NASDAQ: AMGN) following FDA panel recommendation for Repatha but notes commentary points to a narrower label.
Somaiya commented, "We believe the recent FDA Advisory Committee panels... More
Cowen Maintains Bullish View on Amgen (AMGN) Following Panel Repatha In Familial Hypercholesterolemia
June 11, 2015 7:13 AM EDTCowen analyst Eric Schmidt reiterating an Outperform rating and $189 price target on Amgen (NASDAQ: AMGN) after an FDA panel backed Repatha in familial hypercholesterolemia.
Analyst Erich Schmidt commented, "The FDA's EMDAC panel recommended Repatha be approved for HoFH (15:0 vote) and one more additional very... More
UPDATE: Amgen (AMGN) Wins FDA Panel Backing for Repatha
June 10, 2015 3:57 PM EDT(Updated - June 10, 2015 4:26 PM EDT)
An FDA panel voted 11-4 to back Amgen's (NASDAQ: AMGN) Repatha in some patients. The panel also backed the drug for HoFH with a vote of 15-0.
Repatha is an investigational fully human monoclonal antibody that inhibits... More
